The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Overview of attention for article published in Investigational New Drugs, April 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (77th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

patent: 5 patents

Citations

dimensions_citation: 63 Dimensions

Readers on

mendeley: 42 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 5 patents that reference this research output.

Combination therapy of HSP90 inhibitors with platinum-containing agents

Grant US-10500193-B2

United States of America

COMPOSITIONS AND METHODS FOR DETERMINING A TREATMENT COURSE OF ACTION

Application WO-2018127786-A1

World Intellectual Property Organisation (WIPO)

Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors

Grant US-9439899-B2

United States of America

Combination therapy of HSP90 inhibitors with BRAF inhibitors

Grant US-9402831-B2

United States of America

Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor

Grant US-9205086-B2

United States of America